Skip to main content
. 2022 Feb 17;13:806837. doi: 10.3389/fphar.2022.806837

FIGURE 4.

FIGURE 4

Engraftment and reconstruction of human UCB CD34+CD38−CD45RA−CD90+ cells before (fresh) and after a 4-d culture with DMSO, SR1, LA alone, or in combination with SR1 (LA + SR1) in sublethal irradiated NOG mice. (A) Schematic representation of xenograft experiment. NOG mice were transplanted with 300 fresh or cultured cells (n = 6 mice per group). (B) Human engraftment in peripheral blood (PB) of NOG mice was detected at 4-, 8-, and 12-weeks post-transplantation and mice were sacrificed at 16-weeks post-transplantation for bone marrow (BM) analysis. (B) The percentage of human CD45+ cells in PB of NOG mice. Numbers of mice with ≥2% engraftment percentage are specified. (C) The percentage of human CD45+ cells in BM of NOG mice (upper panel) and the number of mice at different engraftment levels (<15%; 15%–30%; 30%–45%; >45%) (lower panel) in each group at 16-weeks post-transplantation. (D) Levels of myeloid (CD45+CD33+), B lymphocytes (CD45+CD19+), T lymphocytes (CD45+CD3+), natural killer cells (CD45+CD56+), megakaryocytes (CD45−CD41a+), and erythroid (CD45−CD235a+) reconstitution in BM of NOG mice at 16-weeks post-transplantation. (E) Representative FACS profiles showing engraftment of human CD45+ cells and multilineage reconstruction described in (C,D).